Investigation · Quebec · Ongoing

714-X: Quebec's Fifty-Year Cancer "Cure"

A product that's mostly water has survived a manslaughter trial, an FDA health-fraud ban, and a government crackdown — and is still legally distributed in Canada today.

Status: still available via Health Canada's Special Access Programme as of 2026

Unlike most cases on this site, 714-X isn't a fly-by-night operator who might close up shop after enough scrutiny. It's a product that has been manufactured continuously in Quebec since the early 1970s, survived a criminal trial, an FDA ban, and a federal regulatory fight — and remains legally obtainable in Canada right now.

Who Made It

Gaston Naessens, a French biologist, had already been tried in France for practicing medicine without a license before relocating to Quebec in the early 1970s. There he developed 714-X — a name he chose from his own initials (7th and 14th letters of the alphabet) and his birth year, 1924. He marketed it as a treatment for cancer, multiple sclerosis, fibromyalgia, and other serious diseases, claiming it worked by counteracting the harm done by "somatids" — a purported life form belonging to no domain recognized by actual biology.

What It Actually Is

714-X is advertised as containing camphor combined with nitrogen, ammonium salts, sodium chloride, and ethanol, typically injected into the lymphatic system through the groin or inhaled via nebulizer. An FDA laboratory analysis found it to be 94% water, with the remainder mostly salts and less than 0.01% camphor. No studies on its safety or efficacy in humans have ever been published, and the limited animal studies conducted showed no beneficial effect. The American Cancer Society states plainly that there is no scientific evidence 714-X is effective in treating any type of cancer or any other illness.

Timeline

Where the Real Harm Is

The product itself, as independently analyzed, is close to pharmacologically inert — mostly water and salt. The documented harm isn't chemical toxicity; it's opportunity cost. Patients with a serious or terminal diagnosis who choose 714-X, or delay conventional treatment to try it first, are making that trade against a product with no published evidence of benefit in humans. The 1989 case is the starkest example: a woman died after refusing conventional cancer treatment in favour of 714-X alone.